With over 400 million chronic patients, India stands as one of the world’s largest pharmaceutical markets. While most e-pharmacies race to deliver medicines faster, the bigger challenge — high drug prices — remains unresolved.
Founded in 2019, Truemeds chose a different route: recommending quality-assured, lower-cost generic medicines as alternatives to expensive branded drugs. This approach has paid off — the company recently secured $85 million in new funding, lifting its valuation from $110 million two years ago to over $400 million today.
Funding details
The latest round was led by Accel, with participation from Peak XV Partners, WestBridge Capital, and InfoEdge Ventures. Of the $85 million raised, $65 million came in primary capital and $20 million in secondary transactions.
A strategic pivot in a crowded market
When Truemeds entered the market, India’s online pharmacy segment was already saturated with big players offering steep discounts on branded generics. Some of these giants later lost momentum — PharmEasy, for example, saw its valuation tumble from $5.6 billion to under $600 million, while 1mg was acquired by Tata Digital.
Instead of competing head-on, Truemeds zeroed in on the generic drug segment.
“It’s difficult yet essential to convince patients that there are more affordable options without compromising quality,” said co-founder Akshat Nayyar. “We saw that no one in the value chain was filling this gap — so we decided to bridge it.”
Growth in numbers
- 66% annual revenue growth, reaching ₹5 billion ($57M) in the last fiscal year
- 75% of customers from tier-2 cities and beyond
- 500,000 monthly active users, totaling 3 million to date
- Service coverage across 20,000+ postal codes in India
Prioritizing savings over speed
As other e-pharmacies reduced their average discounts — from 25% to 15% — Truemeds moved in the opposite direction. In the past year, its average discount rose from 29% to 32%, and users who switch brands save an average of 47% on their prescriptions.
These savings stem from deep partnerships with pharmaceutical manufacturers, allowing for better demand forecasting and production planning through technology.
What’s next: AI and diagnostics
Truemeds conducts 10–12 million consultations annually, using proprietary algorithms to recommend the most suitable generics. Factors considered include whether a medicine is sugar-coated (important for young patients), where it’s manufactured, and whether the facility is GMP-certified.
Next, the company plans to launch AI-driven personalized consultations, tailoring conversations based on past customer behavior. It also aims to expand into diagnostics through partnerships with national pathology labs, starting with pilot programs in tier-2 cities in the next few months.
Additionally, the startup will quadruple its fulfillment centers — from 19 to 76 — over the next year to strengthen its market presence.
The mission remains unchanged: making healthcare more affordable for the end user. While it started with medicines, the model is now expanding into diagnostics and other healthcare segments.
